Oncologists' attitudes toward KRAS testing: a multisite study

Recent discoveries promise increasingly to help oncologists individually tailor anticancer therapy to their patients’ molecular tumor characteristics. One such promising molecular diagnostic is Kirsten ras (KRAS) tumor mutation testing for metastatic colorectal cancer (mCRC) patients. In the current...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Julie N, Liljestrand, Petra, Alexander, Gwen L, Goddard, Katrina A B, Kauffman, Tia, Kolevska, Tatjana, McCarty, Catherine, O'Neill, Suzanne, Pawloski, Pamala, Rahm, Alanna, Williams, Andrew, Somkin, Carol P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892392/
https://www.ncbi.nlm.nih.gov/pubmed/24403261
http://dx.doi.org/10.1002/cam4.135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892392/
https://www.ncbi.nlm.nih.gov/pubmed/24403261
http://dx.doi.org/10.1002/cam4.135

Ejemplares similares